- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Hemab Therapeutics Holdings, Inc. Common Stock(COAG)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for COAG
11/13/2026: COAG (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing prophylactic antibody therapies for rare and severe blood coagulation disorders. The company's primary strength lies in its specialized pipeline of differentiated assets like sutacimig (HMB-001) and HMB-002, which address significant unmet needs in bleeding disorders. Its core investment story centers on high-growth potential driven by upcoming clinical milestones, backed by cash reserves secured from its 2026 public market debut. However, the company faces substantial execution risks, zero commercial revenue, and typical pre-commercial biotechnology volatility. This stock suits growth-oriented investors with high risk tolerance, who should closely monitor clinical trial readouts and regulatory updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers high-growth potential driven by clinical-stage rare disease drug development milestones. |
| Momentum investor | Strong fit while signal remains positive | Short-term price action responds dynamically to clinical data readouts and broader biotech sector momentum. |
| Value investor | Weak fit | The absence of commercial revenue and current earnings makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company pays no dividends and retains all capital to fund clinical research. |
| Low-risk investor | Weak fit | High clinical development risks and share price volatility present substantial risk for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience sharp price swings around clinical updates and market conditions. |
| Valuation risk | Medium / high | Valuation relies heavily on future clinical success and regulatory approvals rather than current earnings. |
| Competition risk (rare disease and gene therapy competition) | Medium / high | Well-funded competitors are constantly developing alternative therapies for rare bleeding disorders. |
| Business quality | Medium | The science is promising, but the business lacks commercial-stage validation or diversified revenue streams. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term. |
| Execution risk | High | Success depends entirely on cleanly executing complex clinical trials and securing regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.91B USD | Price to earnings Ratio - | 1Y Target Price 63 |
Price to earnings Ratio - | 1Y Target Price 63 | ||
Volume (30-day avg) 479.0K shares | Beta - | 52 Weeks Range 18.00 - 55.42 | Updated Date 11/15/2026 |
52 Weeks Range 18.00 - 55.42 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.55 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 30.06% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic Licensing and Commercialization (Future) | Anticipated future revenue from commercialized proprietary antibody therapeutics and potential milestone or royalty payments from licensing agreements. | The company currently generates no revenue and relies on equity financing while advancing its drug candidates toward market approval. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.48B | Price to Sales(TTM) - |
Enterprise Value 1.48B | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 46.73M | Shares Floating 17.96M |
Shares Outstanding 46.73M | Shares Floating 17.96M | ||
Percent Insiders 11 | Percent Institutions 97.98 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

